{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:01:27Z","timestamp":1784584887948,"version":"3.55.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-026-01942-5","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:22:22Z","timestamp":1784535742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From glycemic control to neuroprotection: alogliptin as a repurposed candidate for Huntington\u2019s disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Garima","family":"Choudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Vashisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra Singh","family":"Ashawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-2774","authenticated-orcid":false,"given":"Shiv Kumar","family":"Kushawaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1942_CR1","doi-asserted-by":"publisher","first-page":"116994","DOI":"10.1016\/j.taap.2024.116994","volume":"489","author":"AH Abdelhamid","year":"2024","unstructured":"Abdelhamid AH et al (2024) Neuroprotective effects of saxagliptin against radiation-induced cognitive impairment: Insights on Akt\/CREB\/SIRT1\/BDNF signaling pathway. Toxicol Appl Pharmcol 489:116994. https:\/\/doi.org\/10.1016\/j.taap.2024.116994","journal-title":"Toxicol Appl Pharmcol"},{"issue":"19","key":"1942_CR2","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2174\/0115680266293416240515075450","volume":"24","author":"M Abubakar","year":"2024","unstructured":"Abubakar M et al (2024) GLP-1\/GIP agonist as an intriguing and ultimate remedy for combating alzheimer\u2019s disease through its supporting DPP4 inhibitors: a review. Curr Top Med Chem 24(19):1635\u20131664. https:\/\/doi.org\/10.2174\/0115680266293416240515075450","journal-title":"Curr Top Med Chem"},{"key":"1942_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neuroscience.2018.07.033","volume":"403","author":"M Aiello","year":"2019","unstructured":"Aiello M et al (2019) Neuroinflammation in neurodegenerative diseases: current multi-modal imaging studies and future opportunities for hybrid PET\/MRI. Neuroscience 403:125\u2013135. https:\/\/doi.org\/10.1016\/j.neuroscience.2018.07.033","journal-title":"Neuroscience"},{"key":"1942_CR4","doi-asserted-by":"publisher","first-page":"12019","DOI":"10.2147\/dddt.s576701","volume":"19","author":"AH Al Khzem","year":"2025","unstructured":"Al Khzem AH, Wali SM (2025) Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review. Drug Des Devel Ther 19:12019\u201312034. https:\/\/doi.org\/10.2147\/dddt.s576701","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"1942_CR5","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s11033-026-11738-6","volume":"53","author":"A Alkhammash","year":"2026","unstructured":"Alkhammash A, Alotaibi G (2026) Decoding ferroptosis and apoptosis crosstalk in glioblastoma: molecular mechanisms, microenvironmental regulation, and therapeutic advances. Mol Biol Rep 53(1):562","journal-title":"Mol Biol Rep"},{"issue":"12","key":"1942_CR6","doi-asserted-by":"publisher","first-page":"e70277","DOI":"10.1002\/pds.70277","volume":"34","author":"C Aloke","year":"2025","unstructured":"Aloke C et al (2025) Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. Pharmacoepidemiol Drug Saf 34(12):e70277. https:\/\/doi.org\/10.1002\/pds.70277","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1942_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","volume":"71","author":"T Alqahtani","year":"2023","unstructured":"Alqahtani T et al (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and amyotrophic lateral sclerosis-an updated review. Mitochondrion 71:83\u201392. https:\/\/doi.org\/10.1016\/j.mito.2023.05.007","journal-title":"Mitochondrion"},{"issue":"2","key":"1942_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00441-022-03593-1","volume":"388","author":"AE Alsemeh","year":"2022","unstructured":"Alsemeh AE, Abdullah DM (2022) Protective effect of alogliptin against cyclophosphamide-induced lung toxicity in rats: Impact on PI3K\/Akt\/FoxO1 pathway and downstream inflammatory cascades. Cell Tissue Res 388(2):417\u2013438. https:\/\/doi.org\/10.1007\/s00441-022-03593-1","journal-title":"Cell Tissue Res"},{"issue":"4","key":"1942_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/molecules26040889","volume":"26","author":"BM Ayoub","year":"2021","unstructured":"Ayoub BM et al (2021) Repurposing of omarigliptin as a neuroprotective agent based on docking with A2A adenosine and AChE receptors, brain GLP-1 response and its brain\/plasma concentration ratio after 28 days multiple doses in rats using LC-MS\/MS. Molecules 26(4):889. https:\/\/doi.org\/10.3390\/molecules26040889","journal-title":"Molecules"},{"issue":"4","key":"1942_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11011-025-01584-z","volume":"40","author":"B Baral","year":"2025","unstructured":"Baral B et al (2025) Neuroprotective effects of Saxagliptin in traumatic brain injury: ameliorating oxidative stress, neuroinflammation, and apoptosis. Metab Brain Dis 40(4):175. https:\/\/doi.org\/10.1007\/s11011-025-01584-z","journal-title":"Metab Brain Dis"},{"issue":"9","key":"1942_CR12","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.3390\/ijms25094900","volume":"25","author":"AA Boshchenko","year":"2024","unstructured":"Boshchenko AA et al (2024) Peptides are cardioprotective drugs of the future: the receptor and signaling mechanisms of the cardioprotective effect of glucagon-like peptide-1 receptor agonists. Int J Mol Sci 25(9):4900","journal-title":"Int J Mol Sci"},{"issue":"458","key":"1942_CR13","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne LM et al (2018) Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci Transl Med 10(458):eaat7108. https:\/\/doi.org\/10.1126\/scitranslmed.aat7108","journal-title":"Sci Transl Med"},{"key":"1942_CR14","unstructured":"Candeias EM (2021) The amazing anti-type 2 diabetic drugs in neurodegeneration: The impact of exendin-4, liraglutide and linagliptin in type 2 diabetes, Alzheimer\u2019s disease and Parkinson\u2019s disease. Universidade de Coimbra (Portugal).1-184"},{"key":"1942_CR114","doi-asserted-by":"crossref","unstructured":"Cao S et al (2024) The effect of macrophage-cardiomyocyte interactions on cardiovascular diseases and development of potential drugs. Mol Biol Rep 51(1):1056","DOI":"10.1007\/s11033-024-09944-1"},{"key":"1942_CR15","doi-asserted-by":"publisher","unstructured":"Carmo C et al (2018) Mitochondrial dysfunction in Huntington\u2019s disease. Mitochondrial dysfunction in Huntington\u2019s disease. In: N\u00f3brega C, de Almeida PL (eds) Polyglutamine disorders. Advances in Experimental Medicine and Biology, vol 1049. Springer, Cham, pp 59\u201383. https:\/\/doi.org\/10.1007\/978-3-319-71779-1_3","DOI":"10.1007\/978-3-319-71779-1_3"},{"issue":"1","key":"1942_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12933-018-0702-3","volume":"17","author":"F Chiazza","year":"2018","unstructured":"Chiazza F et al (2018) The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1\u03b1\/CXCR4 pathway. Cardiovasc Diabetol 17(1):60. https:\/\/doi.org\/10.1186\/s12933-018-0702-3","journal-title":"Cardiovasc Diabetol"},{"key":"1942_CR17","doi-asserted-by":"publisher","first-page":"611735","DOI":"10.3389\/fcell.2020.611735","volume":"8","author":"M Czeredys","year":"2020","unstructured":"Czeredys M (2020) Dysregulation of neuronal calcium signaling via store-operated channels in Huntington\u2019s disease. Front Cell Dev Biology 8:611735. https:\/\/doi.org\/10.3389\/fcell.2020.611735","journal-title":"Front Cell Dev Biology"},{"key":"1942_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.mito.2023.03.001","volume":"70","author":"Y Dai","year":"2023","unstructured":"Dai Y et al (2023) A comprehensive perspective of Huntington\u2019s disease and mitochondrial dysfunction. Mitochondrion 70:8\u201319. https:\/\/doi.org\/10.1016\/j.mito.2023.03.001","journal-title":"Mitochondrion"},{"key":"1942_CR19","doi-asserted-by":"publisher","unstructured":"Dhingra H, Gaidhane SA (2023) Huntington\u2019s disease: understanding its novel drugs and treatments. Cureus, 15(10):: e47526. https:\/\/doi.org\/10.7759\/cureus.47526","DOI":"10.7759\/cureus.47526"},{"key":"1942_CR20","doi-asserted-by":"publisher","first-page":"176635","DOI":"10.1016\/j.ejphar.2024.176635","volume":"975","author":"M Dhureja","year":"2024","unstructured":"Dhureja M, Deshmukh R (2024) Impact of alogliptin on lipopolysaccharide-induced experimental Parkinson\u2019s disease: Unrevealing neurochemical and histopathological alterations in rodents. Eur J Pharmacol 975:176635. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176635","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1942_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/17460441.2023.2294118","volume":"19","author":"M Dichiara","year":"2024","unstructured":"Dichiara M et al (2024) Designing drugs optimized for both blood\u2013brain barrier permeation and intra-cerebral partition. Expert Opin Drug Discov 19(3):317\u2013329. https:\/\/doi.org\/10.1080\/17460441.2023.2294118","journal-title":"Expert Opin Drug Discov"},{"key":"1942_CR22","unstructured":"Dobson L (2017) Investigation into pathological neuronal-myeloid cell interactions and rescue of hyper-reactive immune responses in Huntington\u2019s disease. UCL (University College London, pp 1\u201330"},{"key":"1942_CR23","doi-asserted-by":"publisher","first-page":"1033479","DOI":"10.3389\/fendo.2022.1033479","volume":"13","author":"H Du","year":"2022","unstructured":"Du H et al (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease. Front Endocrinol 13:1033479. https:\/\/doi.org\/10.3389\/fendo.2022.1033479","journal-title":"Front Endocrinol"},{"key":"1942_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.lfs.2015.01.030","volume":"126","author":"AE El-Sahar","year":"2015","unstructured":"El-Sahar AE et al (2015) Sitagliptin attenuates transient cerebral ischemia\/reperfusion injury in diabetic rats: Implication of the oxidative\u2013inflammatory\u2013apoptotic pathway. Life Sci 126:81\u201386. https:\/\/doi.org\/10.1016\/j.lfs.2015.01.030","journal-title":"Life Sci"},{"issue":"2","key":"1942_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/ijnp\/pyaa078","volume":"24","author":"AE El-Sahar","year":"2021","unstructured":"El-Sahar AE et al (2021) Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4\/MYD88\/NF-\u03baB and miRNA-155\/SOCS-1 signaling pathways. Int J Neuropsychopharmacol 24(2):158\u2013169. https:\/\/doi.org\/10.1093\/ijnp\/pyaa078","journal-title":"Int J Neuropsychopharmacol"},{"key":"1942_CR26","doi-asserted-by":"crossref","unstructured":"El-Sayed SS et al (2024) Potential neuroprotective and autophagy-enhancing effects of alogliptin on lithium\/pilocarpine-induced seizures in rats: Targeting the AMPK\/SIRT1\/Nrf2 axis. 352:122917. Life sciences10.1016\/j.lfs.2024.122917","DOI":"10.1016\/j.lfs.2024.122917"},{"issue":"1","key":"1942_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11033-025-10458-7","volume":"52","author":"T Elemary","year":"2025","unstructured":"Elemary T et al (2025) The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions. Mol Biol Rep 52(1):400","journal-title":"Mol Biol Rep"},{"issue":"19","key":"1942_CR28","doi-asserted-by":"publisher","first-page":"9608","DOI":"10.3390\/ijms26199608","volume":"26","author":"MM Fahmy","year":"2025","unstructured":"Fahmy MM et al (2025) Alogliptin Mitigates Methotrexate-Induced Nephrotoxicity in a Rat Model: Antagonizing Oxidative Stress, Inflammation and Apoptosis. Int J Mol Sci 26(19):9608. https:\/\/doi.org\/10.3390\/ijms26199608","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1942_CR29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1089\/ars.2019.8004","volume":"34","author":"L F\u00e3o","year":"2021","unstructured":"F\u00e3o L, Rego AC (2021) Mitochondrial and redox-based therapeutic strategies in Huntington\u2019s disease. Antioxid Redox Signal 34(8):650\u2013673. https:\/\/doi.org\/10.1089\/ars.2019.8004","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"1942_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/mdc3.70010","volume":"12","author":"M Farag","year":"2025","unstructured":"Farag M et al (2025) Neuroimaging techniques in Huntington\u2019s disease: a critical review. Mov Disorders Clin Pract 12(5):561\u2013576. https:\/\/doi.org\/10.1002\/mdc3.70010","journal-title":"Mov Disorders Clin Pract"},{"issue":"3","key":"1942_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1080\/15548627.2020.1728096","volume":"17","author":"S Franco-Iborra","year":"2021","unstructured":"Franco-Iborra S et al (2021) Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease. Autophagy 17(3):672\u2013689. https:\/\/doi.org\/10.1080\/15548627.2020.1728096","journal-title":"Autophagy"},{"issue":"6","key":"1942_CR32","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/antiox11061060","volume":"11","author":"E Galatou","year":"2022","unstructured":"Galatou E et al (2022) Nonalcoholic steatohepatitis (NASH) and atherosclerosis: explaining their pathophysiology, association and the role of incretin-based drugs. Antioxidants 11(6):1060. https:\/\/doi.org\/10.3390\/antiox11061060","journal-title":"Antioxidants"},{"issue":"6","key":"1942_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/157339910793499119","volume":"6","author":"SB Ghatak","year":"2010","unstructured":"Ghatak SB et al (2010) Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev 6(6):410\u2013421. https:\/\/doi.org\/10.2174\/157339910793499119","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"1942_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1389450115666140115113734","volume":"15","author":"J Gil-Mohapel","year":"2014","unstructured":"Gil-Mohapel J, Brocardo PS, Christie BR (2014) The role of oxidative stress in Huntington\u2019s disease: are antioxidants good therapeutic candidates? Curr Drug Targets 15(4):454\u2013468","journal-title":"Curr Drug Targets"},{"key":"1942_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2020.00178","volume":"11","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE (2020) GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne) 11:178. https:\/\/doi.org\/10.3389\/fendo.2020.00178","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"1942_CR35","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.3390\/ijms23116089","volume":"23","author":"L G\u00f3mez-Jaramillo","year":"2022","unstructured":"G\u00f3mez-Jaramillo L et al (2022) A new perspective on Huntington\u2019s disease: how a neurological disorder influences the peripheral tissues. Int J Mol Sci 23(11):6089. https:\/\/doi.org\/10.3390\/ijms23116089","journal-title":"Int J Mol Sci"},{"key":"1942_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.biopha.2018.10.064","volume":"109","author":"F Hao","year":"2019","unstructured":"Hao F et al (2019) The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother 109:181\u2013187. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.064","journal-title":"Biomed Pharmacother"},{"key":"1942_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/jdi.12446","volume":"7","author":"T Hirano","year":"2016","unstructured":"Hirano T, Mori Y (2016) Anti-atherogenic and anti\u2010inflammatory properties of glucagon\u2010like peptide\u20101, glucose\u2010dependent insulinotropic polypeptide, and dipeptidyl peptidase\u20104 inhibitors in experimental animals. J diabetes Invest 7:80\u201386. https:\/\/doi.org\/10.1111\/jdi.12446","journal-title":"J diabetes Invest"},{"key":"1942_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","volume":"136","author":"C H\u00f6lscher","year":"2018","unstructured":"H\u00f6lscher C (2018) Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models. Neuropharmacology 136:251\u2013259. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.040","journal-title":"Neuropharmacology"},{"key":"1942_CR39","doi-asserted-by":"publisher","first-page":"898955","DOI":"10.3389\/fphar.2022.898955","volume":"13","author":"H Hong","year":"2022","unstructured":"Hong H et al (2022) A review of the pharmacological effects of paeoniflorin in the nervous system. Front Pharmacol 13:898955. https:\/\/doi.org\/10.3389\/fphar.2022.898955","journal-title":"Front Pharmacol"},{"issue":"1","key":"1942_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.13005\/bbra\/3210","volume":"21","author":"GB Jadhav","year":"2024","unstructured":"Jadhav GB et al (2024) Evaluation of Protective Effect of Gemigliptin and Rizatriptan in Streptozotocin induced Diabetic Neuropathy in Rats. Biosci Biotechnol Res Asia 21(1):147\u2013156","journal-title":"Biosci Biotechnol Res Asia"},{"key":"1942_CR41","doi-asserted-by":"publisher","first-page":"1361651","DOI":"10.3389\/fphar.2024.1361651","volume":"15","author":"X Jiang","year":"2024","unstructured":"Jiang X et al (2024) Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer\u2019s disease: a narrative review. Front Pharmacol 15:1361651. https:\/\/doi.org\/10.3389\/fphar.2024.1361651","journal-title":"Front Pharmacol"},{"issue":"7","key":"1942_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a024240","volume":"7","author":"M Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez M et al (2017) Huntington\u2019s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. Cold Spring Harb Perspect Med 7(7):1\u201323. https:\/\/doi.org\/10.1101\/cshperspect.a024240","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"1942_CR43","doi-asserted-by":"publisher","first-page":"e01029","DOI":"10.1002\/prp2.1029","volume":"10","author":"L Jones","year":"2022","unstructured":"Jones L, Jones AM (2022) Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? Pharmacol Res Perspect 10(6):e01029. https:\/\/doi.org\/10.1002\/prp2.1029","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"1942_CR44","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s40264-019-00857-8","volume":"42","author":"K Kaku","year":"2019","unstructured":"Kaku K et al (2019) Benefit-risk assessment of alogliptin for the treatment of type 2 diabetes mellitus. Drug Saf 42(11):1311\u20131327. https:\/\/doi.org\/10.1007\/s40264-019-00857-8","journal-title":"Drug Saf"},{"issue":"6","key":"1942_CR45","first-page":"736","volume":"12","author":"MA Kamel","year":"2022","unstructured":"Kamel MA, Mohamed SS (2022) Nephroprotective effect of Alogliptin and L-Carnitine in Gentamicin-induced Toxicity in male Albino rats. J Adv Veterinary Res 12(6):736\u2013742","journal-title":"J Adv Veterinary Res"},{"issue":"1","key":"1942_CR46","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","volume":"22","author":"N Krishnamurthy","year":"2022","unstructured":"Krishnamurthy N et al (2022) Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res 22(1):970. https:\/\/doi.org\/10.1186\/s12913-022-08272-z","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"1942_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/jhd-160205","volume":"5","author":"A Kumar","year":"2016","unstructured":"Kumar A, Ratan RR (2016) Oxidative Stress and Huntington\u2019s Disease: The Good, The Bad, and The Ugly. J Huntingtons Dis 5(3):217\u2013237. https:\/\/doi.org\/10.3233\/jhd-160205","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"1942_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10048-025-00801-2","volume":"26","author":"OK Kunwar","year":"2025","unstructured":"Kunwar OK, Singh S (2025) Neuroinflammation and neurodegeneration in Huntington\u2019s disease: genetic hallmarks, role of metals and organophosphates. Neurogenetics 26(1):21. https:\/\/doi.org\/10.1007\/s10048-025-00801-2","journal-title":"Neurogenetics"},{"issue":"7","key":"1942_CR49","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00228-023-03506-3","volume":"79","author":"E Kutoh","year":"2023","unstructured":"Kutoh E et al (2023) Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid. Eur J Clin Pharmacol 79(7):947\u2013959. https:\/\/doi.org\/10.1007\/s00228-023-03506-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20133","key":"1942_CR50","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejphar.2008.04.047","volume":"589","author":"B Lee","year":"2008","unstructured":"Lee B et al (2008) Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 589(1\u20133):306\u2013314","journal-title":"Eur J Pharmacol"},{"key":"1942_CR51","doi-asserted-by":"publisher","first-page":"101673","DOI":"10.1016\/j.bbrep.2024.101673","volume":"38","author":"M Lee","year":"2024","unstructured":"Lee M et al (2024) Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway. Biochem Biophys Rep 38:101673. https:\/\/doi.org\/10.1016\/j.bbrep.2024.101673","journal-title":"Biochem Biophys Rep"},{"issue":"17","key":"1942_CR52","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1021\/acs.jmedchem.3c00412","volume":"66","author":"Q Li","year":"2023","unstructured":"Li Q et al (2023) Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants. J Med Chem 66(17):11593\u201311631. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00412","journal-title":"J Med Chem"},{"issue":"21","key":"1942_CR53","doi-asserted-by":"publisher","first-page":"11787","DOI":"10.3390\/ijms252111787","volume":"25","author":"X Li","year":"2024","unstructured":"Li X et al (2024a) Neuroinflammatory proteins in Huntington\u2019s disease: insights into mechanisms, diagnosis, and therapeutic implications. Int J Mol Sci 25(21):11787. https:\/\/doi.org\/10.3390\/ijms252111787","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1942_CR54","doi-asserted-by":"publisher","first-page":"e23750","DOI":"10.1016\/j.heliyon.2023.e23750","volume":"10","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024b) Formononetin ameliorates cisplatin-induced hair cell death via activation of the PI3K\/AKT-Nrf2 signaling pathway. Heliyon 10(1):e23750","journal-title":"Heliyon"},{"key":"1942_CR55","doi-asserted-by":"publisher","first-page":"114464","DOI":"10.1016\/j.bcp.2021.114464","volume":"186","author":"Y Lu","year":"2021","unstructured":"Lu Y et al (2021) Minocycline promotes functional recovery in ischemic stroke by modulating microglia polarization through STAT1\/STAT6 pathways. Biochem Pharmacol 186:114464. https:\/\/doi.org\/10.1016\/j.bcp.2021.114464","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1942_CR56","doi-asserted-by":"publisher","first-page":"e3841","DOI":"10.1002\/dmrr.3841","volume":"40","author":"Y Luo","year":"2024","unstructured":"Luo Y et al (2024) Progress in the pathogenesis of diabetic encephalopathy: the key role of neuroinflammation. Diab\/Metab Res Rev 40(6):e3841","journal-title":"Diab\/Metab Res Rev"},{"issue":"15","key":"1942_CR57","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.3390\/ijms26157520","volume":"26","author":"CF Manful","year":"2025","unstructured":"Manful CF et al (2025) Antioxidants and reactive oxygen species: shaping human health and disease outcomes. Int J Mol Sci 26(15):7520","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1942_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17925\/ee.2024.20.2.5","volume":"20","author":"SA Mangoura","year":"2024","unstructured":"Mangoura SA et al (2024) New Insights into the Pleiotropic Actions of Dipeptidyl Peptidase-4 Inhibitors Beyond Glycaemic Control. touchREV Endocrinol 20(2):19\u201329. https:\/\/doi.org\/10.17925\/ee.2024.20.2.5","journal-title":"touchREV Endocrinol"},{"issue":"12","key":"1942_CR59","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/brainsci14121191","volume":"14","author":"V Mani","year":"2024","unstructured":"Mani V, Arfeen M (2024) In vivo and computational studies on sitagliptin\u2019s neuroprotective role in type 2 diabetes mellitus: implications for Alzheimer\u2019s disease. Brain Sci 14(12):1191. https:\/\/doi.org\/10.3390\/brainsci14121191","journal-title":"Brain Sci"},{"issue":"2","key":"1942_CR60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3892\/br.2016.569","volume":"4","author":"T Mashitani","year":"2016","unstructured":"Mashitani T et al (2016) Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomedical Rep 4(2):183\u2013187. https:\/\/doi.org\/10.3892\/br.2016.569","journal-title":"Biomedical Rep"},{"key":"1942_CR61","doi-asserted-by":"publisher","unstructured":"Monti G et al (2022) GLP-1 receptor agonists in neurodegeneration: neurovascular unit in the spotlight. Cells, 11(13): 2023. https:\/\/doi.org\/10.3390\/cells11132023","DOI":"10.3390\/cells11132023"},{"issue":"3","key":"1942_CR62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/jhd-170253","volume":"6","author":"MT Montojo","year":"2017","unstructured":"Montojo MT et al (2017) Huntington\u2019s Disease and Diabetes: Chronological Sequence of its Association. J Huntingtons Dis 6(3):179\u2013188. https:\/\/doi.org\/10.3233\/jhd-170253","journal-title":"J Huntingtons Dis"},{"issue":"4","key":"1942_CR63","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.3390\/ijms24043748","volume":"24","author":"I Moratilla-Rivera","year":"2023","unstructured":"Moratilla-Rivera I et al (2023) Natural products as modulators of Nrf2 signaling pathway in neuroprotection. Int J Mol Sci 24(4):3748","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1942_CR64","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.3390\/ijms24076051","volume":"24","author":"E Morena","year":"2023","unstructured":"Morena E et al (2023) Peripheral biomarkers in manifest and premanifest Huntington\u2019s disease. Int J Mol Sci 24(7):6051. https:\/\/doi.org\/10.3390\/ijms24076051","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1942_CR65","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4103\/1673-5374.249217","volume":"14","author":"SA Mousa","year":"2019","unstructured":"Mousa SA, Ayoub BM (2019) Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents. Neural regeneration Res 14(5):745\u2013748. https:\/\/doi.org\/10.4103\/1673-5374.249217","journal-title":"Neural regeneration Res"},{"issue":"1","key":"1942_CR66","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","volume":"28","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Edison P (2023) Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease. Mol Psychiatry 28(1):217\u2013229","journal-title":"Mol Psychiatry"},{"issue":"24","key":"1942_CR67","doi-asserted-by":"publisher","first-page":"12163","DOI":"10.3390\/ijms262412163","volume":"26","author":"MP Orozco","year":"2025","unstructured":"Orozco MP, Vintimilla Rivadeneira V, Leon-Rojas JE (2025) GLP-1 Signalling as a Therapeutic Avenue in Parkinson\u2019s Disease: A Comprehensive Review. Int J Mol Sci 26(24):12163","journal-title":"Int J Mol Sci"},{"key":"1942_CR68","doi-asserted-by":"publisher","first-page":"829966","DOI":"10.3389\/fphar.2022.829966","volume":"13","author":"S Pan","year":"2022","unstructured":"Pan S et al (2022) Indole-3-carbinol selectively prevents chronic stress-induced depression-but not anxiety-like behaviors via suppressing pro-inflammatory cytokine production and oxido-nitrosative stress in the brain. Front Pharmacol 13:829966. https:\/\/doi.org\/10.3389\/fphar.2022.829966","journal-title":"Front Pharmacol"},{"issue":"6","key":"1942_CR69","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/brainsci7060067","volume":"7","author":"RA Paoli","year":"2017","unstructured":"Paoli RA et al (2017) Neuropsychiatric burden in Huntington\u2019s disease. Brain Sci 7(6):67. https:\/\/doi.org\/10.3390\/brainsci7060067","journal-title":"Brain Sci"},{"issue":"4","key":"1942_CR70","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/ijms23042388","volume":"23","author":"R Pariyar","year":"2022","unstructured":"Pariyar R et al (2022) Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson\u2019s Disease. Int J Mol Sci 23(4):2388. https:\/\/doi.org\/10.3390\/ijms23042388","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1942_CR71","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00702-025-02907-1","volume":"132","author":"HY Park","year":"2025","unstructured":"Park HY et al (2025) Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson\u2019s disease. J Neural Transm 132(6):827\u2013843. https:\/\/doi.org\/10.1007\/s00702-025-02907-1","journal-title":"J Neural Transm"},{"key":"1942_CR72","doi-asserted-by":"publisher","first-page":"1642333","DOI":"10.3389\/fphar.2025.1642333","volume":"16","author":"KT Pavlovi\u0107","year":"2025","unstructured":"Pavlovi\u0107 KT, Anderluh M, \u0160melcerovi\u0107 A (2025) Mechanisms of beneficial effects of DPP-4 inhibitors as a promising perspective for the prevention\/treatment of the disruption of cardio-cerebrovascular homeostasis. Front Pharmacol 16:1642333","journal-title":"Front Pharmacol"},{"key":"1942_CR73","doi-asserted-by":"publisher","first-page":"821113","DOI":"10.3389\/fendo.2022.821113","volume":"13","author":"C Pelusi","year":"2022","unstructured":"Pelusi C (2022) The effects of the new therapeutic treatments for diabetes mellitus on the male reproductive axis. Front Endocrinol 13:821113. https:\/\/doi.org\/10.3389\/fendo.2022.821113","journal-title":"Front Endocrinol"},{"issue":"9\u201310","key":"1942_CR74","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1159\/000505132","volume":"105","author":"J Qiu","year":"2020","unstructured":"Qiu J et al (2020) Lipopolysaccharide-induced depression-like behaviors is ameliorated by sodium butyrate via inhibiting neuroinflammation and oxido-nitrosative stress. Pharmacology 105(9\u201310):550\u2013560. https:\/\/doi.org\/10.1159\/000505132","journal-title":"Pharmacology"},{"key":"1942_CR75","doi-asserted-by":"publisher","first-page":"173522","DOI":"10.1016\/j.ejphar.2020.173522","volume":"889","author":"SO Rahman","year":"2020","unstructured":"Rahman SO et al (2020) Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer\u2019s disease. Eur J Pharmacol 889:173522. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173522","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1942_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11481-025-10271-w","volume":"21","author":"HA Raslan","year":"2026","unstructured":"Raslan HA et al (2026) Repositioning of Alogliptin to Mitigate Secondary Injury Induced by Repetitive TBI: Potential Role of its Antioxidant and Anti-Inflammatory Effects. J Neuroimmune Pharmacol 21(1):6. https:\/\/doi.org\/10.1007\/s11481-025-10271-w","journal-title":"J Neuroimmune Pharmacol"},{"key":"1942_CR77","doi-asserted-by":"publisher","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review. Front NeuroSci 16:970925","journal-title":"Front NeuroSci"},{"issue":"11","key":"1942_CR78","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1038\/s41591-025-03920-3","volume":"31","author":"R Reilmann","year":"2025","unstructured":"Reilmann R et al (2025) Pridopidine in early-stage manifest Huntington\u2019s disease: a phase 3 trial. Nat Med 31(11):3780\u20133789. https:\/\/doi.org\/10.1038\/s41591-025-03920-3","journal-title":"Nat Med"},{"issue":"6","key":"1942_CR79","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2174\/1570159X19666211201094608","volume":"20","author":"J Saba","year":"2022","unstructured":"Saba J et al (2022) Neuroinflammation in Huntington\u2019s disease: a starring role for astrocyte and microglia. Curr Neuropharmacol 20(6):1116\u20131143. https:\/\/doi.org\/10.2174\/1570159X19666211201094608","journal-title":"Curr Neuropharmacol"},{"issue":"10","key":"1942_CR80","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1007\/s12035-023-03433-5","volume":"60","author":"G Sahoo","year":"2023","unstructured":"Sahoo G et al (2023) A review on caspases: key regulators of biological activities and apoptosis. Mol Neurobiol 60(10):5805\u20135837. https:\/\/doi.org\/10.1007\/s12035-023-03433-5","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1942_CR81","doi-asserted-by":"publisher","first-page":"9494","DOI":"10.1038\/s41598-025-90896-2","volume":"15","author":"J Sato","year":"2025","unstructured":"Sato J et al (2025) Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment. Sci Rep 15(1):9494. https:\/\/doi.org\/10.1038\/s41598-025-90896-2","journal-title":"Sci Rep"},{"issue":"15","key":"1942_CR82","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2165\/11205080-000000000-00000","volume":"70","author":"LJ Scott","year":"2010","unstructured":"Scott LJ (2010) Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 70(15):2051\u20132072. https:\/\/doi.org\/10.2165\/11205080-000000000-00000","journal-title":"Drugs"},{"key":"1942_CR83","doi-asserted-by":"publisher","first-page":"123307","DOI":"10.1016\/j.lfs.2024.123307","volume":"361","author":"SM Selim","year":"2025","unstructured":"Selim SM et al (2025) Alogliptin attenuates STZ-induced diabetic nephropathy in rats through the modulation of autophagy, apoptosis, and inflammation pathways: Targeting NF-\u03baB and AMPK\/mTOR pathway. Life Sci 361:123307. https:\/\/doi.org\/10.1016\/j.lfs.2024.123307","journal-title":"Life Sci"},{"key":"1942_CR84","doi-asserted-by":"publisher","first-page":"1191629","DOI":"10.3389\/fncel.2023.1191629","volume":"17","author":"R She","year":"2023","unstructured":"She R et al (2023) Mitochondrial dysfunctions induce PANoptosis and ferroptosis in cerebral ischemia\/reperfusion injury: from pathology to therapeutic potential. Front Cell Neurosci 17:1191629","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"1942_CR85","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10928-025-09961-y","volume":"52","author":"C Shen","year":"2025","unstructured":"Shen C et al (2025) A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment. J Pharmacokinet Pharmacodyn 52(1):13. https:\/\/doi.org\/10.1007\/s10928-025-09961-y","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1942_CR86","doi-asserted-by":"publisher","unstructured":"Shi SM, Di L (2022) Strategies to optimize peptide stability and prolong half-life Peptide therapeutics: fundamentals of design, development, and delivery. 163\u2013182: Cham. https:\/\/doi.org\/10.1007\/978-3-031-04544-8_4","DOI":"10.1007\/978-3-031-04544-8_4"},{"issue":"9","key":"1942_CR87","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1007\/s11064-023-03924-w","volume":"48","author":"N Siddiqui","year":"2023","unstructured":"Siddiqui N et al (2023) Neuroprotective role of DPP-4 inhibitor linagliptin against neurodegeneration, neuronal insulin resistance and neuroinflammation induced by intracerebroventricular streptozotocin in rat model of Alzheimer\u2019s disease. Neurochem Res 48(9):2714\u20132730. https:\/\/doi.org\/10.1007\/s11064-023-03924-w","journal-title":"Neurochem Res"},{"issue":"22","key":"1942_CR88","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.3390\/cells11223631","volume":"11","author":"P Sileo","year":"2022","unstructured":"Sileo P et al (2022) Crosstalk between the Hippo pathway and the Wnt pathway in Huntington\u2019s disease and other neurodegenerative disorders. Cells 11(22):3631. https:\/\/doi.org\/10.3390\/cells11223631","journal-title":"Cells"},{"issue":"6","key":"1942_CR89","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4103\/2230-8210.141319","volume":"18","author":"AK Singh","year":"2014","unstructured":"Singh AK (2014) Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions. Indian J Endocrinol Metab 18(6):753\u2013759. https:\/\/doi.org\/10.4103\/2230-8210.141319","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"1942_CR90","doi-asserted-by":"publisher","first-page":"154916842614175","DOI":"10.1177\/15491684261417549","volume":"29","author":"G Singh","year":"2026","unstructured":"Singh G et al (2026) Huntington\u2019s Disease: An Overview of Biomarkers in Prognostic, Diagnostic, and Therapeutic Management. Rejuven Res 29(4):15491684261417549. https:\/\/doi.org\/10.1177\/15491684261417549","journal-title":"Rejuven Res"},{"issue":"4","key":"1942_CR91","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jnc.14723","volume":"150","author":"AI Smith-Dijak","year":"2019","unstructured":"Smith-Dijak AI et al (2019) Alterations in synaptic function and plasticity in Huntington disease. J Neurochem 150(4):346\u2013365. https:\/\/doi.org\/10.1111\/jnc.14723","journal-title":"J Neurochem"},{"issue":"1","key":"1942_CR94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11(1):42\u201353. https:\/\/doi.org\/10.1016\/S1474-4422(11)70263-0","journal-title":"Lancet Neurol"},{"issue":"10","key":"1942_CR93","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ et al (2020) Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Reviews Neurol 16(10):529\u2013546. https:\/\/doi.org\/10.1038\/s41582-020-0389-4","journal-title":"Nat Reviews Neurol"},{"issue":"7","key":"1942_CR92","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi SJ et al (2022) Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol 21(7):645\u2013658. https:\/\/doi.org\/10.1016\/S1474-4422(22)00121-1","journal-title":"Lancet Neurol"},{"issue":"33","key":"1942_CR95","doi-asserted-by":"publisher","first-page":"e4541","DOI":"10.1097\/MD.0000000000004541","volume":"95","author":"H Tai","year":"2016","unstructured":"Tai H et al (2016) The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. Medicine 95(33):e4541. https:\/\/doi.org\/10.1097\/MD.0000000000004541","journal-title":"Medicine"},{"issue":"1","key":"1942_CR96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12993-022-00187-3","volume":"18","author":"M Talebi","year":"2022","unstructured":"Talebi M et al (2022) The interplay between oxidative stress and autophagy: focus on the development of neurological diseases. Behav Brain Funct 18(1):3. https:\/\/doi.org\/10.1186\/s12993-022-00187-3","journal-title":"Behav Brain Funct"},{"issue":"1","key":"1942_CR97","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/med.21513","volume":"39","author":"K Tomovic","year":"2019","unstructured":"Tomovic K et al (2019) Mechanisms and pathways of anti-inflammatory activity of DPP\u20104 inhibitors in cardiovascular and renal protection. Med Res Rev 39(1):404\u2013422. https:\/\/doi.org\/10.1002\/med.21513","journal-title":"Med Res Rev"},{"issue":"6","key":"1942_CR98","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/biomedicines12061314","volume":"12","author":"BS Tudurachi","year":"2024","unstructured":"Tudurachi BS et al (2024) Unraveling the cardiac matrix: from diabetes to heart failure, exploring pathways and potential medications. Biomedicines 12(6):1314","journal-title":"Biomedicines"},{"issue":"1","key":"1942_CR99","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12035-026-05772-5","volume":"63","author":"S Upadhayay","year":"2026","unstructured":"Upadhayay S (2026) Role of Pentacyclic Triterpenes in the Management of Neurological Disorders: An Insight into Molecular Mechanisms and Therapeutic Approaches. Mol Neurobiol 63(1):516. https:\/\/doi.org\/10.1007\/s12035-026-05772-5","journal-title":"Mol Neurobiol"},{"issue":"11","key":"1942_CR100","doi-asserted-by":"publisher","first-page":"14367","DOI":"10.1007\/s12035-025-04962-x","volume":"62","author":"S Upadhayay","year":"2025","unstructured":"Upadhayay S et al (2025) Role of fibroblast growth factors in neurological disorders: insight into therapeutic approaches and molecular mechanisms. Mol Neurobiol 62(11):14367\u201314386. https:\/\/doi.org\/10.1007\/s12035-025-04962-x","journal-title":"Mol Neurobiol"},{"issue":"5","key":"1942_CR101","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/ph18050614","volume":"18","author":"M Urkon","year":"2025","unstructured":"Urkon M et al (2025) Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of Alzheimer\u2019s disease. Pharmaceuticals 18(5):614","journal-title":"Pharmaceuticals"},{"issue":"9","key":"1942_CR102","doi-asserted-by":"publisher","first-page":"8336","DOI":"10.18632\/aging.205333","volume":"16","author":"W Wang","year":"2023","unstructured":"Wang W, Zhang J (2023) Teneligliptin alleviates diabetes-related cognitive impairment by inhibiting the endoplasmic reticulum (ER) stress and NLRP3 inflammasome in mice. Aging 16(9):8336. https:\/\/doi.org\/10.18632\/aging.205333","journal-title":"Aging"},{"key":"1942_CR103","doi-asserted-by":"publisher","unstructured":"Wici\u0144ski M et al (2019) Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases. Int J Mol Sci 20(16). https:\/\/doi.org\/10.3390\/ijms20164052","DOI":"10.3390\/ijms20164052"},{"issue":"4","key":"1942_CR104","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1210\/endrev\/bnaf006","volume":"46","author":"MM Wolfe","year":"2025","unstructured":"Wolfe MM et al (2025) Glucose-dependent insulinotropic polypeptide in incretin physiology: role in health and disease. Endocr Rev 46(4):479\u2013500. https:\/\/doi.org\/10.1210\/endrev\/bnaf006","journal-title":"Endocr Rev"},{"issue":"1","key":"1942_CR105","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.xphs.2023.09.006","volume":"113","author":"N Wu","year":"2024","unstructured":"Wu N, An G (2024) A quantitative systems pharmacology model of the incretin hormones GIP and GLP1, glucagon, glucose, insulin, and the small molecule DPP-4 inhibitor, linagliptin. J Pharm Sci 113(1):278\u2013289. https:\/\/doi.org\/10.1016\/j.xphs.2023.09.006","journal-title":"J Pharm Sci"},{"issue":"1","key":"1942_CR106","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/13880209.2021.1876101","volume":"59","author":"G Xu","year":"2021","unstructured":"Xu G, Guo J, Sun C (2021) Eucalyptol ameliorates early brain injury after subarachnoid haemorrhage via antioxidant and anti-inflammatory effects in a rat model. Pharm Biol 59(1):112\u2013118. https:\/\/doi.org\/10.1080\/13880209.2021.1876101","journal-title":"Pharm Biol"},{"issue":"5","key":"1942_CR107","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","volume":"26","author":"X Yang","year":"2022","unstructured":"Yang X et al (2022) Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson\u2019s disease. Expert Opin Ther Targets 26(5):445\u2013460. https:\/\/doi.org\/10.1080\/14728222.2022.2079492","journal-title":"Expert Opin Ther Targets"},{"key":"1942_CR108","doi-asserted-by":"publisher","unstructured":"Yin R et al (2022) Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment. Molecules 27(10). https:\/\/doi.org\/10.3390\/molecules27103055","DOI":"10.3390\/molecules27103055"},{"issue":"4","key":"1942_CR109","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s13205-026-04761-8","volume":"16","author":"M Yizibula","year":"2026","unstructured":"Yizibula M et al (2026) Neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson\u2019s disease via autophagy modulation. 3 Biotech 16(4):146. https:\/\/doi.org\/10.1007\/s13205-026-04761-8","journal-title":"3 Biotech"},{"key":"1942_CR110","doi-asserted-by":"publisher","unstructured":"Yuan Y et al (2024) Effects of DPP4 Inhibitors as Neuroprotective Drug on Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review. Int J Endocrinol 9294113. https:\/\/doi.org\/10.1155\/2024\/9294113","DOI":"10.1155\/2024\/9294113"},{"key":"1942_CR111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fnmol.2018.00329","volume":"11","author":"J Zheng","year":"2018","unstructured":"Zheng J et al (2018) A mitochondria-associated oxidative stress perspective on Huntington\u2019s disease. Front Mol Neurosci 11:329. https:\/\/doi.org\/10.3389\/fnmol.2018.00329","journal-title":"Front Mol Neurosci"},{"issue":"11","key":"1942_CR112","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.3390\/biomedicines11113035","volume":"11","author":"M Z\u0142otek","year":"2023","unstructured":"Z\u0142otek M et al (2023) GLP-1 analogs, SGLT-2, and DPP-4 inhibitors: a triad of hope for Alzheimer\u2019s disease therapy. Biomedicines 11(11):3035","journal-title":"Biomedicines"},{"key":"1942_CR113","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12013-025-01959-0","volume":"84","author":"A Zulqarnain","year":"2025","unstructured":"Zulqarnain A et al (2025) The Intricate Role of Caspase-6 and Death Receptor-6 in Neurodegenerative Diseases. Cell Biochem Biophys 84:505\u2013523. https:\/\/doi.org\/10.1007\/s12013-025-01959-0","journal-title":"Cell Biochem Biophys"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01942-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01942-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01942-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:01:55Z","timestamp":1784581315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01942-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1942"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01942-5","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"169"}}